🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. teclistamab, teclistamab, JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  2. tobacco abstinent contingent

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 other completed

    1 trial

  3. tocilizumab [RoActemra/Actemra]

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  4. toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  5. trastuzumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 mab active

    1 trial

  6. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  7. ublituximab, DEXAMETHASONE, PARACETAMOL, GADOBUTROL, ublituximab placebo, DIPHENHYDRAMINE, CETIRIZINE, METHYLPREDNISOLONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  8. vinflunine

    Pierre Fabre Medicament

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  9. volrustomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  10. ziltivekimab, Placebo (ziltivekimab C)

    NovoThirteen

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial

  11. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  12. ​Placebo to Osimertinib - Film-coated tablet - 40mg / 80mg, CARBOPLATIN, TAGRISSO 80 mg film-coated tablets, CISPLATIN, PEMETREXED, PEMETREXED, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    tardive dyskinesia

    phase 2 small molecule active

    1 trial

  14. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  15. (+)-α-DIHYDROTETRABENAZINE, ADE513 placebo

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  16. -

    Ningbo Cancer Hospital

    Unresectable intrahepatic cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  17. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  18. -, -, PACLITAXEL , MK-2870, -, MK-1022, RAMUCIRUMAB , MK-2870, PARACETAMOL

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  19. -, -, ROXATIDINE , RANITIDINE , OSIMERTINIB , NIZATIDINE , SKB264, CIMETIDINE , FAMOTIDINE, COMBINATIONS, FAMOTIDINE , CARBOPLATIN , PARACETAMOL , PEMBROLIZUMAB , OSIMERTINIB, -

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  21. -, CYCLOPHOSPHAMIDE, Cesnicabtagene autoleucel, PARACETAMOL, FLUDARABINE, LENALIDOMIDE, RoActemra 20 mg/mL concentrate for solution for infusion

    The George Institute

    Plasma cell leukaemia

    phase 2 small molecule active

    1 trial

  22. -, MERCAPTOPURINE , -, Film-Coated Tablet without JNJ-77242113, JNJ-77242113, AZATHIOPRINE , METHOTREXATE , JNJ-77242113

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  23. -, PREDNISONE, PARACETAMOL , FLUDROCORTISONE , ABIRATERONE , -, HYDROCORTISONE, -, Ifinatamab Deruxtecan, -, -, HYDROCORTISONE, HYDROCORTISONE, Opevesostat, DOCETAXEL , ENZALUTAMIDE , PREDNISOLONE

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 small molecule active

    1 trial

  24. -, Pred Forte 10 mg/ml colirio en suspensión

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources